Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Adenocarcinoma; Breast cancer
- Focus Therapeutic Use
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 10 Jun 2017 Biomarkers information updated
- 23 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.